Ovid Therapeutics Inc.
OVID- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001636651
No open-market purchases or sales by Ovid Therapeutics Inc. insiders were filed in the last 90 days; 130 institutions reported holding it in 13F filings for Q2 2026, worth $395.5M in total; no superinvestor holds it.
13F holders, Q2 2026
Institutional positions in Ovid Therapeutics Inc. as of Jun 30, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 130
- +28 vs. Q1 2026
- Shares held
- 147.0M
- +52.6M (+55.8%) vs. Q1 2026
- Total value
- $395.5M
- +$186.0M (+88.8%) vs. Q1 2026
- New holders
- 46
- 33 more added
- Sold out
- 18
- 27 more reduced
1 institution that held it in Q1 2026 haven't filed for Q2 2026 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q1 2026: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting OVID on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 130 | $395.5M |
| Q1 2026 | 103 | $233.2M |
| Q4 2025 | 84 | $100.5M |
| Q3 2025 | 81 | $47.1M |
| Q2 2025 | 71 | $11.9M |
| Q1 2025 | 82 | $14.5M |
| Q4 2024 | 82 | $44.4M |
| Q3 2024 | 75 | $56.4M |
| Q2 2024 | 74 | $36.5M |
| Q1 2024 | 81 | $158.7M |
| Q4 2023 | 77 | $172.0M |
| Q3 2023 | 64 | $162.6M |
| Q2 2023 | 69 | $134.5M |
| Q1 2023 | 61 | $100.0M |
| Q4 2022 | 60 | $71.7M |
| Q3 2022 | 59 | $65.5M |
| Q2 2022 | 55 | $74.5M |
| Q1 2022 | 62 | $110.3M |
| Q4 2021 | 67 | $110.1M |
| Q3 2021 | 72 | $112.9M |
| Q2 2021 | 80 | $130.5M |
| Q1 2021 | 88 | $145.7M |
Institutions, Q2 2026
Shares, value and share of portfolio for each institution holding Ovid Therapeutics Inc.; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Boothbay Fund Management, LLC | 737,758 | $1.98M | 0.04% | −190,155−20.5% | Reduced |
| OrbiMed Advisors LLC | 747,000 | $2.01M | 0.04% | +747,000 | New |
| Wells Fargo & Company | 826,206 | $2.22M | 0.00% | +112,581+15.8% | Added |
| Two Sigma Investments, LP | 832,378 | $2.24M | 0.00% | −424,491−33.8% | Reduced |
| Nuveen, LLC | 893,254 | $2.40M | 0.00% | +893,254 | New |
| Ensign Peak Advisors, Inc | 988,084 | $2.66M | 0.00% | +988,084 | New |
| Sio Capital Management, LLC | 1,005,334 | $2.70M | 0.46% | −247,047−19.7% | Reduced |
| Vanguard Portfolio Management LLC | 1,030,943 | $2.77M | 0.00% | +1,030,943 | New |
| Rosalind Advisors, Inc. | 1,107,994 | $2.98M | 1.12% | 00.0% | Unchanged |
| Propel Bio Management, LLC | 1,115,538 | $3.00M | 1.57% | +194,081+21.1% | Added |
| Vanguard Fiduciary Trust Co | 1,140,753 | $3.07M | 0.00% | +447,497+64.6% | Added |
| Northern Trust Corp | 1,246,139 | $3.35M | 0.00% | +991,335+389.1% | Added |
| Sphera Funds Management Ltd. | 1,353,000 | $3.64M | 0.52% | −269,828−16.6% | Reduced |
| Point72 Asset Management, L.P. | 1,945,727 | $5.23M | 0.01% | +625,117+47.3% | Added |
| Ikarian Capital, LLC | 2,269,704 | $6.11M | 1.00% | −625,000−21.6% | Reduced |
| StemPoint Capital LP | 2,417,283 | $6.50M | 1.13% | +2,417,283 | New |
| Silverarc Capital Management, LLC | 3,101,129 | $8.34M | 0.93% | +2,101,129+210.1% | Added |
| Geode Capital Management, LLC | 4,072,653 | $11.0M | 0.00% | +2,754,562+209.0% | Added |
| Braidwell LP | 5,919,464 | $15.9M | 0.59% | +5,919,464 | New |
| Federated Hermes, Inc. | 5,951,666 | $16.0M | 0.02% | +2,380,666+66.7% | Added |
| Adage Capital Partners GP, L.L.C. | 6,163,781 | $16.6M | 0.02% | 00.0% | Unchanged |
| Balyasny Asset Management LLC | 6,719,076 | $18.1M | 0.03% | +1,186,003+21.4% | Added |
| ADAR1 Capital Management, LLC | 7,417,479 | $20.0M | 0.94% | +2,873,366+63.2% | Added |
| Vanguard Capital Management LLC | 7,760,114 | $20.9M | 0.00% | +2,501,868+47.6% | Added |
| State Street Corp | 7,900,765 | $21.3M | 0.00% | +7,380,482+1,418.6% | Added |
| Affinity Asset Advisors, LLC | 10,144,562 | $27.3M | 1.33% | −491,756−4.6% | Reduced |
| Ra Capital Management, L.P. | 10,500,968 | $28.2M | 0.25% | −213,032−2.0% | Reduced |
| BlackRock, Inc. | 10,823,480 | $29.1M | 0.00% | +9,290,197+605.9% | Added |
| Eventide Asset Management, LLC | 11,812,241 | $31.8M | 0.42% | +1,895,330+19.1% | Added |
| Jupiter Topco LLC | 20,741,234 | $55.9M | 0.02% | +20,741,234 | New |
| Blue Owl Capital Holdings LP | 0 | $0 | 0.00% | −1,904,666−100.0% | Sold out |
| Marshall Wace, LLP | 0 | $0 | 0.00% | −917,733−100.0% | Sold out |
| Jane Street Group, LLC | 0 | $0 | 0.00% | −735,429−100.0% | Sold out |
| Walleye Capital LLC | 0 | $0 | 0.00% | −443,362−100.0% | Sold out |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −367,902−100.0% | Sold out |
| Simplify Asset Management Inc. | 0 | $0 | 0.00% | −130,813−100.0% | Sold out |
| Gsa Capital Partners LLP | 0 | $0 | 0.00% | −123,969−100.0% | Sold out |
| Quadrature Capital Ltd | 0 | $0 | 0.00% | −111,804−100.0% | Sold out |
| Brevan Howard Capital Management LP | 0 | $0 | 0.00% | −101,759−100.0% | Sold out |
| Omers Administration Corp | 0 | $0 | 0.00% | −100,100−100.0% | Sold out |
| Qube Research & Technologies Ltd | 0 | $0 | 0.00% | −94,301−100.0% | Sold out |
| Axq Capital, LP | 0 | $0 | 0.00% | −85,411−100.0% | Sold out |
| Diametric Capital, LP | 0 | $0 | 0.00% | −43,262−100.0% | Sold out |
| Mangrove Partners | 0 | $0 | 0.00% | −27,294−100.0% | Sold out |
| Prelude Capital Management, LLC | 0 | $0 | 0.00% | −10,951−100.0% | Sold out |
| Simplex Trading, LLC | 0 | $0 | 0.00% | −3,674−100.0% | Sold out |
| Advisory Services Network, LLC | 0 | $0 | 0.00% | −219−100.0% | Sold out |
| Sound Income Strategies, LLC | 0 | $0 | 0.00% | −6−100.0% | Sold out |
| Janus Henderson Group PLC | – | – | – | – | Not filed |